• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN SA Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Dose Maintenance, Reduction With Antipsychotics

Dose Maintenance, Reduction With Antipsychotics

June 1, 2018
Adam Strassberg, MD.
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Adam Strassberg, MD. Dr. Strassberg has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.
Review of: Zhou Y et al, Journal of Psychopharmacology 2018. doi:10.1177/0269881118756062

Once patients with schizophrenia are stabilized on an antipsychotic in the acute phase of their treatment, guidelines are unclear on how to continue dosing. Some guidelines recommend lowering the dose, others recommend maintaining the dose, and others give no firm recommendations whatsoever.

For fear of relapse, many clinicians never lower the dose, so many patients are simply kept on the higher acute-phase doses. These doses can be associated with more side effects, including extrapyramidal symptoms, metabolic syndrome, and impaired cognitive function.

This 52-week, single-blinded (rater-blinded), randomized controlled study sought data on maintenance and reduction using 2 frequently prescribed antipsychotics. Relapse was defined as a score of ≥ 4 on the Positive and Negative Syndrome Scale (PANSS) on at least one of the following: delusion, conceptual disorganization, hallucinatory behavior, or suspiciousness.

Researchers studied 75 stabilized schizophrenic patients, who were prescribed either risperidone (≥ 4 mg/day) or olanzapine (≥ 10 mg/day). They were randomly divided into a maintenance group (n = 38) and a dose-reduction group (n = 37).

In the maintenance group, the dose of medication remained unchanged. In the dose-reduction group, the dose of antipsychotic was reduced by 25% for the first 4 weeks, then reduced by 50% of the original dose for the remaining 48 weeks. Doses were never lowered below minimum recommendations—ie, below 2 mg/day for risperidone or below 5 mg/day for olanzapine.

Over 52 weeks, relapse rates were not significantly different between the groups, with relapse of only 4 patients in the dose-reduction group and 6 patients in the maintenance group.

A 50% dose reduction of antipsychotics did not lead to any worsening of psychotic symptoms. In fact, patients on the lower doses had fewer extrapyramidal symptoms (p = 0.012), lower body mass index (p = 0.005), improved cognitive function (p = 0.001), and improved negative symptoms overall (p < 0.001).

TCPR’s Take
Despite a small sample size, using single rather than double blinding, and being limited to only 2 antipsychotics, this study offers much-needed evidence to guide some important clinical decisions. During the maintenance phase with our stabilized schizophrenic patients, careful antipsychotic dose reduction (by 25% over the first 4 weeks, and then by 50% thereafter) is worth trying.
General Psychiatry
KEYWORDS antipsychotics research-update
Adam Strassberg, MD.

Can Mindfulness-Based Stress Reduction Affect Symptom Outcomes in Older Adults?

More from this author
www.thecarlatreport.com
Issue Date: June 1, 2018
SUBSCRIBE NOW
Table Of Contents
CME Post-Test - Neurobiology, TCPR, June 2018
A Look at the Latest Antidepressant Meta-Analysis
Neurobiology Concepts for Psychiatrists
The Neuroscience Behind Addictions and SSRIs
Dose Maintenance, Reduction With Antipsychotics
Lithium Favored in Treatment Effectiveness Study
DOWNLOAD NOW
Featured Book
  • MFB6eCover.jpg

    Medication Fact Book for Psychiatric Practice, Sixth Edition (2022)

    Guidance, clinical pearls, and bottom-line assessments covering the medications you use in your...
    READ MORE
Featured Video
  • therapist_canstockphoto9201097.jpg
    General Psychiatry

    Using SAMe In Clinical Practice with Garrett Rossi, MD

    Read More
Featured Podcast
  • canstockphoto4921771.jpg
    General Psychiatry

    Psychopharm Commandment #6: MAOIs

    MAOIs rank high in efficacy and are pretty well tolerated too, as long as you watch for two critical interactions.

    Listen now
Recommended
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png

About

  • About Us
  • CME Center
  • FAQ
  • Contact Us

Shop Online

  • Newsletters
  • Multimedia Subscriptions
  • Books
  • eBooks
  • ABPN Self-Assessment Courses

Newsletters

  • The Carlat Psychiatry Report
  • The Carlat Child Psychiatry Report
  • The Carlat Addiction Treatment Report
  • The Carlat Hospital Psychiatry Report
  • The Carlat Geriatric Psychiatry Report

Contact

info@thecarlatreport.com

866-348-9279

PO Box 626, Newburyport MA 01950

Follow Us

Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

© 2023 Carlat Publishing, LLC and Affiliates, All Rights Reserved.